GlassScriptPhysician profile
Markey C Mcnutt
NPI 1679893010
$246,965.34
in general payments reported to CMS, 2019-2025
19 companies · $147K in 2025
The $147K reported for 2025 was more than what 99% of Clinical Genetics (M.D.) providers received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,867 · 2020: $11K · 2021: $6,276 · 2022: $21K · 2023: $16K · 2024: $39K · 2025: $147K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $177K · Honoraria: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,288 · Travel and Lodging: $4,601 · Food and Beverage: $2,730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $176,714.41 |
| Honoraria | $11,600.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,288.00 |
| Travel and Lodging | $4,600.55 |
| Food and Beverage | $2,729.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $148,672.42 | 2020-2025 | |
| Biomarin Pharmaceutical INC. | $39,624.30 | 2019-2025 | Palynziq |
| Horizon Therapeutics Plc | $25,279.43 | 2019-2023 | Ravicti |
| Amicus Therapeutics, INC. | $7,527.00 | 2024-2025 | Opfolda, Pombiliti |
| Amgen INC. | $7,317.76 | 2024-2025 | Ravicti |
| Chiesi USA, INC. | $4,925.12 | 2022-2024 | Lamzede |
| Ptc Therapeutics, INC. | $3,660.91 | 2022-2025 | Sephience |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $3,559.26 | 2024-2025 | |
| Mirum Pharmaceuticals, INC. | $1,625.00 | 2025 | Ctexli |
| Eton Pharmaceuticals, INC. | $1,327.47 | 2022-2025 | Nitisinone, Betaine Anhydrous, Galzin |
| Applied Therapeutics, INC. | $1,125.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $820.00 | 2023 | Strensiq |
| Modernatx, INC. | $636.02 | 2024 | |
| Cycle Pharmaceuticals INC | $600.00 | 2020 | |
| Genzyme Corporation | $175.72 | 2021-2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intrabio INC | $36.99 | 2025 | Aqneursa |
| Orchard Therapeutics North America | $26.48 | 2025 | Lenmeldy |
| Dexcom, INC. | $17.02 | 2024 | Dexcom G6 Transmitter |
| Travere Therapeutics, INC. | $9.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Markey Mcnutt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.